{"contentid": 488280, "importid": NaN, "name": "US NIH to investigate allergic reactions after mRNA-based vaccines", "introduction": "In the USA, the National Institutes of Health (NIH) is to initiate a Phase II trial to investigate the causes of certain allergic reactions to mRNA-based vaccines.", "content": "<p><span style=\"font-weight: 400;\">In the USA, the National Institutes of Health (NIH) is to initiate a Phase II trial to investigate the causes of certain allergic reactions to mRNA-based vaccines.</span></p>\n<p><span style=\"font-weight: 400;\">The trial follows reports that a small number of people given Moderna's (Nasdaq: MRNA) mRNA-1273 or Pfizer (NYSE: PFE) and BioNTech's (Nasdaq: BNTX) Comirnaty COVID-19 vaccines had severe allergic reactions.</span></p>\n<p><span style=\"font-weight: 400;\">Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said the goal of the study would be to provide guidance for people who are &ldquo;highly allergic or have a mast cell disorder\" about the risks and benefits associated with the coronavirus vaccines.</span></p>\n<p><span style=\"font-weight: 400;\">The study comes as regulators in the UK and Europe have </span><a href=\"https://www.thepharmaletter.com/article/ema-finds-possible-link-of-astrazeneca-s-covid-19-vaccine-with-rare-blood-clots\"><span style=\"font-weight: 400;\">concluded</span></a><span style=\"font-weight: 400;\"> another coronavirus vaccine, Vaxzevria, from AstraZeneca (LSE: AZN) and Oxford University, could carry a very low risk of a rare, severe blood clot.</span></p>\n<p><span style=\"font-weight: 400;\">Several European countries have advised offering the vaccine to over-30s or older demographics only, while UK Health Secretary Matt Hancock described the level of risk as being comparable to that from a long-haul flight.</span></p>\n<h2><strong>mRNA-based vaccines</strong></h2>\n<p><span style=\"font-weight: 400;\">In a statement, the NIH explained that most of the rare, severe allergic reactions to mRNA-based vaccines have occurred in people with a history of allergies.&nbsp;</span></p>\n<p><span style=\"font-weight: 400;\">The number of cases is very low, and a large number of the people who had a reaction had previously experienced a life-threatening anaphylactic event.</span></p>\n<p><span style=\"font-weight: 400;\">Dr Fauci said: &ldquo;The public understandably has been concerned about reports of rare, severe allergic reactions to the Moderna and Pfizer-BioNTech COVID-19 vaccines.&rdquo;</span></p>\n<p><span style=\"font-weight: 400;\">&ldquo;However, for most people, the benefits of COVID-19 vaccination far outweigh the risks,&rdquo; he added.</span></p>\n<p><span style=\"font-weight: 400;\">The study will enroll 3,400 adults ages 18 to 69 years at up to 35 academic allergy-research centers around the USA, with around 60% of study participants having had a severe allergic reaction in the past, or a diagnosis of a mast cell disorder.</span></p>", "date": "2021-04-08 11:31:00", "meta_title": NaN, "meta_keywords": "allergic, vaccines, reactions, mRNA-based, people, severe, investigate, study, trial, National, Health, number, rare, Institutes, Phase, initiate, Nasdaq", "meta_description": "In the USA, the National Institutes of Health (NIH) is to initiate a Phase II trial to investigate the causes of certain allergic reactions to mRNA-based vaccin", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-08 10:20:17", "updated": "2021-04-08 11:32:29", "access": NaN, "url": "https://www.thepharmaletter.com/article/us-nih-to-investigate-allergic-reactions-after-mrna-based-vaccines", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "nih-big.jpg", "image2id": "nih-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Vaccines", "topic_tag": "Coronavirus, Focus On, Public health, Regulation, US FDA", "geography_tag": "Global, USA", "company_tag": "AstraZeneca, BioNTech, Moderna, National Institutes of Health (NIH), Pfizer", "drug_tag": "Comirnaty, mRNA-1273, Vaxzevria", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-08 11:31:00"}